In CAR T-cell therapy, this feedback loop may provide a means of replicating the “inflamed” immunophenotype of tumours enriched in IFNγ due to DC-mediated antigen presentation to CD4+ and CD8+ T-cells. Here, CD8A is linked to neoplasm.